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The growing interest in the role of Reactive Oxygen Species (ROS) and in the assessment of oxidative stress in health and disease
clashes with the lack of consensus on reliable quantitative noninvasive methods applicable. The study aimed at demonstrating
that a recently developed Electron Paramagnetic Resonance microinvasive method provides direct evidence of the “instantaneous”
presence of ROS returning absolute concentration levels that correlate with “a posteriori” assays of ROS-induced damage by means
of biomarkers. The reliability of the choice to measure ROS production rate in human capillary blood rather than in plasma was
tested (step I). A significant (𝑃 < 0.01) linear relationship between EPR data collected on capillary blood versus venous blood
(𝑅2 = 0.95), plasma (𝑅2 = 0.82), and erythrocytes (𝑅2 = 0.73) was found. Then (step II) ROS production changes of various
subjects’ categories, young versus old and healthy versus pathological at rest condition, were found significantly different (range
0.0001–0.05 𝑃 level). The comparison of the results with antioxidant capacity and oxidative damage biomarkers concentrations
showed that all changes indicating increased oxidative stress are directly related to ROS production increase.Therefore, the adopted
method may be an automated technique for a lot of routine in clinical trials.
1. Introduction
Cells are exposed to a large variety of Reactive Oxygen
Species (ROS) from both exogenous (i.e., pollutants, radi-
ation) and endogenous sources: the latter are the majority,
while mitochondria are the main source of their formation.
At an appropriate concentration, ROS are known to act
as important signaling molecules, essential to cell viability,
playing various regulatory roles inside them [1]. Nevertheless
enhanced levels of ROS overwhelming the cellular antioxi-
dant defense system, phenomenon called oxidative stress, are
implicated in the damage of cellular lipids, proteins, andDNA
[1–3], increase cellular swelling, and decrease cell membrane
fluidity.
High levels of ROS result in several degenerative pro-
cesses and are involved in the etiopathogenesis of sev-
eral pathological states, for example, cardiovascular (i.e.,
ischemia-reperfusion), neurodegenerative (i.e., Parkinson,
Alzheimer, Amyotrophic Lateral Sclerosis, Multiple Sclero-
sis) [4], and inflammatory diseases, cancer [5], and so forth
[6].
ROS also play a key role in a physiological process like
aging. Indeed many reviews have been published regarding
oxidative stress and theory of aging postulating a role of ROS
in the pathogenesis of aging-related diseases [7, 8].
Direct measurements of ROS production are very diffi-
cult due to their high reactivity and low steady-state con-
centration [9]. Thus, oxidative stress assessment is usually
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performed by indirect methods measuring ROS-induced
damage on proteins, membrane lipids, and DNA, the most
vulnerable biological targets for oxidative stress [10, 11].
Thousands of articles have evaluated oxidative damage by
measuring the increase of protein oxidation, by assessing
Protein Carbonyls (PC), as well as lipid peroxidation, by
determining among othersThiobarbituric Acid Reactive Sub-
stances (TBARS), in human blood (primarily in plasma, but
also in serum or blood cells samples).These biomarkers were
altogether found implicated in several pathologies. However
enzymatic assays can be viewed as “a posteriori” methods
with respect to Electron Paramagnetic Resonance (EPR),
the unique technique capable of providing direct detection
of the “instantaneous” presence of free radical species in a
sample [12]. Nevertheless, despite the great potential of EPR
technique, up to now, its use has been far from dominant:
spare works report about free radicals measurement both in
healthy subjects and in patients affected by various diseases,
moreover carried out simply as qualitative methods [13]. It’s
unlikely that clinical EPR will ever become as extensively
and widely utilized as clinical Nuclear Magnetic Resonance,
but for everyone it is important to know the types of mea-
surements that can be performed and their potential clinical
applications. In fact, EPRmay be able to provide useful infor-
mation in a way that offers significant advantages over other
approaches. EPR measurements are possible in vivo using
spin probe or trapping, soluble paramagnetic materials or
labels, returning the possibility of direct observation of ROS
in cells and tissues. Although the experimental application in
animals has been very successful [14], the technique has not
yet been translated to clinical application.The vastmajority of
relevant human studies have measured redox status by using
plasma or serum. This choice was probably adopted after
considering that plasma better reflects tissue redox status
[11] together with the ease of plasma collecting procedure.
However, by this latter choice, potential artifacts generated
by in vitro chemistry during sample preparation cannot
be excluded. Moreover, classic tests have mainly quantified
ROS levels in human plasma but not those associated with
circulating cells, so excluding oxidant-scavenging abilities of
these latter. Indeed red blood cells (RBC) may exert both
antioxidant and prooxidant activity because of the high-iron
concentration depending on the environmental milieu [15].
The goal of the present study was to evaluate the useful-
ness of the EPR technique for the study of ROS production in
biology and medicine by applying an innovative microinva-
sive analytical approach [16] as suitable to be routinely applied
under various pathophysiological states. The methodological
study was carried out in two steps.
Firstly (step I) we aimed at demonstrating the reliability
of our choice to measure ROS production rate in human
capillary blood rather than in plasma as it is usually made.
To this purpose, the relationship between EPR data collected
on capillary versus venous blood and those obtained from
its major components (i.e., plasma and erythrocytes) was
assessed.
Once that the suitability of a widespread use of the afore-
mentioned choice was confirmed, the potential application
of the method as a routine microinvasive analytical tool
to assess “ex vivo” oxidative stress in several physiological
and pathological conditions was investigated (step II). To
this aim, ROS absolute concentration level was measured
in human capillary blood from the most various subjects’
categories: young versus old and healthy versus diseased
people at rest condition. A comparison of the results with
antioxidant capacity and oxidative stress biomarkers concen-
trations determined in the same experiments was attempted
too.
2. Materials and Methods
2.1. Subjects
Step I. ROS production in human blood and its components
was assessed in one hundred healthy middle-aged sedentary
(MS) subjects (34 males (M) and 66 females (F)).
Step II. ROS production was assessed in capillary blood of
seven different subjects’ categories: healthy subjects including
(1) young elite athletes (YA, 𝑛 = 18; male hockey players
from the Varese hockey team), (2) young sedentary (YS,
𝑛 = 32; M), (3) middle-aged sedentary (see step I), and
(4) old sedentary subjects (OS, 𝑛 = 68; 34M and 34 F)
and subjects affected by (5) sarcopenia (SAR, 𝑛 = 25; 13 M
and 12 F; primary sarcopenia: diagnosis in accordance with
European consensus) [17], (6) Mild Cognitive Impairment
(MCI 𝑛 = 19; 10M and 9 F; diagnosis in accordance with
international guidelines) [18], and (7) sporadic Amyotrophic
Lateral Sclerosis (sALS 𝑛 = 22; 14 M and 8 F; diagnosis in
accordance with international guidelines); ALS Functional
Rating Scale Revised, score: 40.1 ± 3.7 (48: normal function;
0: severe disability) [19].
The age and anthropometric characteristics of the partici-
pants are reported in Table 1. In “Healthy” subjects, exclusion
criteria concerning obesity, smoke, alcohol, and current use
of medicines, special diet, minerals, vitamins, or other kind
of supplementation as well as antioxidant supply in the
time course of the study were applied. “Diseased” subjects
showing evidence of target-organ or systemic damage were
excluded, as well as, in the time course of the study, smoke,
alcohol, special diets, minerals, vitamins or other kind of
supplementation and/or antioxidant supply. Administration
of antioxidants has been allowed only to sALS patients:
in these subjects supplementation of vitamins (C, D, and
E) and nutritional supplements such as coenzyme Q10 are
currently recommended [20]. All sALS subjects were in
pharmacological treatment with Riluzole.
All participants, after being informed of all risks, dis-
comforts, and benefits involved in the study, signed a writ-
ten informed consent. Procedures were in accordance with
the Declaration of Helsinki, and institutional review board
approval was received for this study.
2.2. Blood Samples. Approximately 3mL of venous human
blood was drawn from an antecubital vein, with subjects
lying on a bed. The samples were collected in heparinized
Vacutainer tubes (Vacutainer, Becton Dickinson, USA).
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Table 1
Subjects’ features (Caucasian-Italian people)
Healthy Diseased
YA YS MS OS SAR MCI sALS
(𝑛 = 18) (𝑛 = 32) (𝑛 = 100) (𝑛 = 68) (𝑛 = 25) (𝑛 = 19) (𝑛 = 22)
Age (yr) 19.7 ± 1.1 23.0 ± 1.0 47 ± 5.2 72.1 ± 4.5 75.0 ± 5.1 74.3 ± 5.4 56.9 ± 11.9
Weight (kg) 77.6 ± 6.9 78.0 ± 4.8 71.3 ± 8.1 68.8 ± 12.0 79.9 ± 15.6 67.2 ± 12.8 67.6 ± 11.8
Height (m) 1.78 ± 0.04 1.79 ± 0.05 1.69 ± 0.09 1.68 ± 0.09 1.73 ± 0.05 1.64 ± 0.08 1.69 ± 0.08
BMI (kg⋅m−2) 24.6 ± 2.0 23.4 ± 1.8 25.0 ± 3.2 24.1 ± 3.1 27.7 ± 4.2 24.9 ± 3.0 23.58 ± 3.0
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Figure 1: EPR sample preparation and acquisition protocol. CMHSpin Probe (50𝜇L) is added in equal amount (1 : 1) to the collected capillary
blood.The solution is immediately put in a glass EPR tube. From the generated radical compound, in the time course of the reaction, ten EPR
spectra are collected in about 6 minutes, one of which is shown. The signal amplitude (a.u.) is proportional to the number of paramagnetic
spin formed at the acquisition time. The calculated rate production values, converted in absolute levels (𝜇mol⋅min−1) by using CP∙ radical as
external standard, allowed us to significantly discriminate the analyzed subjects’ groups.
Plasma was separated by centrifuge (5702R, Eppendorf,
Germany) at 1000×g for 10min at 4∘C. After removal of
plasma and discarding the buffy coat, aliquots of RBC
were collected. 50 𝜇L of venous blood and of each preva-
lent blood component (i.e., plasma and RBC), immediately
after preparation, was transferred to EPR determinations.
50𝜇L capillary blood was taken from the fingertip and
collected in heparinized capillary tubes (Cholestech LDX,
Germany).
Plasma samples were stored in multiple aliquots at −80∘C
until assayed for oxidative stress biomarkers determination.
Samples were thawed only once before analysis, performed
within two weeks from collection.
2.3. EPR Measurements. An X-band EPR instrument (E-
Scan—Bruker BioSpin, GmbH, MA USA) was adopted for
determinations. The instrument allows us to deal with very
low-concentration amounts of paramagnetic species in small
(50 𝜇L) samples. As is well known, ROS half-life is too
short if compared to the EPR time scale so that they result
in being EPR-invisible but become EPR detectable once
“trapped” and transformed in a more stable radical species.
Among spin trapping or spin probe molecules, suitable for
biological utilization, CMH (1-hydroxy-3-methoxycarbonyl-
2,2,5,5-tetramethylpyrrolidine) probe was adopted.
For each recruited subject, ROS production rate was
determined at rest by means of a recently developed EPR
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method [16] analyzing 50 𝜇L samples immediately treated
with CMH solution (1 : 1). 50𝜇L of the obtained solution was
put in a glass EPR capillary tube (Noxygen Science Transfer
& Diagnostics, Germany) that was placed inside the cavity of
the E-scan spectrometer for data acquisition (Figure 1).
Acquisition parameters were microwave frequency
9.652GHz; modulation frequency 86 kHz; modulation
amplitude 2.28G; sweep width 60G, microwave power
21.90mW, number of scans 10; and receiver gain 3.17⋅101.
Sample temperature was firstly stabilized and then kept at
37∘C by the Temperature & Gas Controller “Bio III” unit,
interfaced to the spectrometer. Spectra were recorded and
analyzed by usingWin EPR software (2.11 version) standardly
supplied by Bruker.
EPR measurements allowed us to attain a relative quan-
titative determination of ROS production rate in samples.
All data were, in turn, converted in absolute concentration
levels (𝜇mol⋅min−1) by adopting CP∙ (3-Carboxy-2,2,5,5-
tetramethyl-1-pyrrolidinyloxy) stable radical as external ref-
erence.
2.4. Enzymatic Assays. Because of difficulty in measuring
each antioxidant component separately and interactions
among antioxidants, the adopted here method assesses the
total antioxidant capacity (TAC) of plasma. Protein Car-
bonyls and Thiobarbituric Acid Reactive Substances were
also determined and used as protein damage and lipid
peroxidation standard indices, respectively.
2.4.1. Total Antioxidant Capacity (TAC). The 6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox-)
equivalent antioxidant capacity assay, a widely used kit-
based commercial method, was used. Briefly, 10 𝜇L of plasma
is added in duplicate to 10 𝜇L of metmyoglobin and 150𝜇L
of the chromogen solution then; reactions are initiated by
the addition of 40 𝜇L of hydrogen peroxide, as indicated
by the manufacturer (Cayman Chemical, USA). Reaction
mixtures are incubated for 3min at room temperature and
then read measuring the absorbance signal at 750 nm by an
Infinite M200 microplate reader spectrophotometer (Tecan,
Austria). A linear calibration curve is computed from pure
Trolox-containing reactions.
2.4.2. Protein Carbonyls (PC). The accumulation of oxidized
proteins was measured by content of reactive carbonyls. A
Protein Carbonyl assay kit (Cayman Chemical, USA) was
used to colorimetrically evaluate oxidized proteins.The sam-
ples were read at 370 nm, by a microplate reader spectropho-
tometer (InfiniteM200, Tecan, Austria), as described in detail
by the manufacturer. Oxidized proteins values obtained were
normalized to the total protein concentration in the final
pellet (absorbance reading at 280 nm), in order to consider
protein loss during the washing steps, as suggested in the kit’s
user manual.
2.4.3. Thiobarbituric Acid Reactive Substances (TBARS). We
usedTBARS assay kit (CaymanChemical,USA)which allows
a rapid photometric detection of the Thiobarbituric Acid
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Figure 2: Histogram plot (mean ± SD) of the absolute ROS pro-
duction rate (𝜇mol⋅min−1) obtained from capillary blood; venous
blood; plasma; and erythrocytes in the same resting healthy subjects.
¶
𝑃 < 0.0001 significant differences.
Malondialdehyde (TBAMDA) adduct at 532 nm. Samples
were read by a microplate reader spectrophotometer (Infinite
M200, Tecan, Austria). A linear calibration curve was com-
puted from pure MDA-containing reactions.
All samples were determined in duplicate and the interas-
say coefficient of variation was in the range indicated by the
manufacturer.
2.5. Statistical Analysis. Numerical values are reported as
mean ± standard deviation (SD). Data were analyzed using
parametric statistics following mathematical confirmation of
a normal distribution using Shapiro-Wilks𝑊 test.
To estimate the significance of ROS production rate in
blood (capillary versus venous, plasma, or erythrocytes) one-
way ANOVA with Bonferroni post hoc test was applied.
Oxidative stress (ROS, TBARS, PC, and TAC) experimen-
tal data were compared using repeated ANOVA measure-
ments with Holm-Sidak’s multiple comparisons test. The
relationship between selected variables was assessed using
Pearson Correlation coefficients. All statistical analyses were
performed by using GraphPad Prism package (GraphPad
Prism 6, Software Inc. San Diego, CA). A P value < 0.05 was
considered statistically significant.
3. Results
3.1. Step I: ROS Production Rate in Blood Components. ROS
production rate in human blood and components is shown
in Figure 2. Different ROS concentrations were obtained by
recording data, on the same resting subject, from the different
blood collections (i.e., capillary and venous) and fractions
(i.e., plasma and RBC). In capillary blood ROS production
level (𝜇mol⋅min−1) was found significantly greater than in
venous (1.91 ± 0.20 versus 1.63 ± 0.29). The greatest level was
found in samples containing only erythrocytes (2.96 ± 0.30).
On the contrary significantly lower levels (0.16 ± 0.02) were
found in plasma samples. Significant (𝑃 < 0.0001) differences
between venous blood versus erythrocytes, venous versus
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Figure 3: Multipanel plots of ROS production rate levels (𝜇mol⋅min−1) measured in capillary blood versus (a) venous blood; (b) plasma; and
(c) erythrocytes (full symbols). The linear regression fit (solid line) is also shown and so is the correlation coefficient (𝑅2) reported in each
panel. A significant linear relationship (¶𝑃 < 0.0001) in the ROS production rate between capillary blood and the other blood components
was estimated.
plasma, and plasma versus erythrocytes were found. The
results are not shown in Figure 2 in order to put in greater
relevance the difference between capillary blood and the
other samples.
The multipanel plots reported in Figure 3 show a signif-
icant linear relationship between the ROS production rate
found in capillary blood and (a) venous blood (𝑅2 = 0.92);
(b) plasma (𝑅2 = 0.82); and (c) erythrocytes (𝑅2 = 0.73).
3.2. Step II: ROS Production Rate and Oxidative Damage:
Resting Data. ROS production rate in capillary blood
(Figure 4(a)), TAC (Figure 4(b)) and oxidative stress
biomarkers concentrations, PC (Figure 4(c)) and TBARS
(Figure 4(d)) in plasma, assessed in healthy and pathological
subjects are displayed.The statistically significant differences,
calculated from the collected data between different groups,
that is, healthy subjects (YA, YS, MS, and OS) and diseased
subjects (SAR, MCI, and sALS), are hereinafter reported.
In particular (Figure 4(a)), a significantly different ROS
production level (𝜇mol⋅min−1) between healthy and diseased
groups was found. In greater detail, significant differences
were calculated as follows:
(i) in the healthy group: YA (2.01±0.09) versus YS (1.84±
0.09) andMS (1.91±0.21); OS (2.12±0.29) versus YS
(1.84 ± 0.09), and MS (1.91 ± 0.21);
(ii) between the healthy and the diseased groups: MS
(1.91 ± 0.21) versus: SAR (2.24 ± 0.26), MCI (2.18 ±
0.31) and, sALS (2.49 ± 0.43); OS versus sALS (2.12 ±
0.29 versus 2.49 ± 0.43);
(iii) in the diseased groups: SAR versus sALS (2.24 ± 0.26
versus 2.49 ± 0.43) and MCI versus sALS (2.18 ± 0.31
versus 2.49 ± 0.43).
In TAC (mM) (Figure 4(b)) significant differences between
the healthy and the diseased groups are as follows: MCI
(1.47 ± 0.38) versus YS (1.91 ± 0.44), MS (1.84 ± 0.43) and
OS (1.81 ± 0.53) are shown.
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Figure 4: Histogram plot (mean ± SD) of (a) ROS production rate obtained from capillary blood samples and plasma concentration levels
of (b) TAC, (c) PC, and (d) TBARS, collected at baseline (rest condition) in healthy (YA, YS, MS, and OS) and pathological subjects (SAR,
MCI, and sALS). ∗𝑃 < 0.05, #𝑃 < 0.01, §𝑃 < 0.001, and ¶𝑃 < 0.0001 significant difference.
Significant difference in PC (nmol⋅mg−1 protein) con-
centration between healthy and diseased groups shows up
(Figure 4(c)). In greater detail significant differences were
calculated as follows:
(i) in the healthy groups: YA versus YS (0.94±0.40 versus
0.76 ± 0.23);
(ii) between the healthy and the pathological groups: MS
versus sALS (0.94±0.36 versus 1.52±0.77), OS (0.91±
0.24) versus SAR (1.15±0.32), and sALS (1.52±0.77);
(iii) in the diseased groups: sALS (1.52±0.77) versus SAR
(1.15 ± 0.32) and MCI (0.91 ± 0.21).
Concerning TBARS concentration (𝜇M) (Figure 4(d)) sig-
nificant differences between healthy and diseased groups
resulted and, in detail, significant differences were calculated
as follows:
(i) in the healthy group: YA (6.74±0.84) versus YS (8.33±
1.38) and OS (9.29 ± 2.61);
(ii) between the healthy and the diseased groups: MS
(7.92 ± 2.64) versus SAR (10.12 ± 3.28), MCI (10.96 ±
2.34), and sALS (12.66±3.79); OS versus sALS (9.29±
2.61 versus 12.66 ± 3.79);
(iii) in the diseased groups: SAR versus sALS (10.12±3.28
versus 12.66 ± 3.79).
Finally, by considering YS and YA groups taken all together
versus single components of the disease group, differences
were found as regard as: (i) ROS production rate levels: (SAR
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Figure 5: Panel plots (for appropriate graphical displays data are reported as mean ± standard error of means—SEM) of ROS production
rate levels (𝜇mol⋅min−1) measured in capillary blood versus (a) PC and (b) TBARS concentrations.The linear regression fit (solid line) is also
shown and so is the correlation coefficient (𝑅2) reported in each panel. A significant linear relationship in the ROS production rate between
PC (𝑃 < 0.01) and TBARS (𝑃 < 0.05) values was estimated.
𝑃 < 0.001; MCI 𝑃 < 0.001; sALS 𝑃 < 0.0001); (ii) PC:
(SAR 𝑃 < 0.001; sALS 𝑃 < 0.0001), and (iii) TBARS: (SAR
𝑃 < 0.001; MCI 𝑃 < 0.001; sALS 𝑃 < 0.0001) (data not
shown).
Figure 5 shows the plot of the correlation between plasma
PC (Figure 5(a)) and TBARS (Figure 5(b)) and ROS produc-
tion values of capillary blood at rest in the examined groups
of subjects. A positive linear relationship was found at rest
between ROS production and plasma PC (𝑅2 = 0.81) and
TBARS (𝑅2 = 0.76) concentrations.
4. Discussion
Themost significant challenges that investigators face in their
attempt to directly assess oxidant levels in vivo are both
the low concentration of ROS present and the extremely
transient nature of these species. The role of free rad-
icals, generated in the biological milieu and propagated
through a cascade of reactions, has been well recognized
in the pathogenesis of many diseases, including a variety of
inflammatory and degenerative pathologies. Much progress
has been made in ROS direct detection, characterization,
and quantification. Indeed Electron Paramagnetic Reso-
nance Spectroscopy detects free radicals and paramagnetic
molecules and plays a major role in the assessment of
most of the oxidants characterized by very short half-life
(nanoseconds to microseconds) usually by using stabilizing
molecules called spin-traps/probes.Themagnetic field-based
EPRdetection enables nondestructive (in vitro) and noninva-
sive (in vivo) measurements of biological samples. Therefore
EPR spectroscopy, coupled with the use of paramagnetic
probes, has become a potential technique for accurate and
precise determination of ROS concentrations in a variety of
biological samples. It was shown [21, 22] that cyclic hydrox-
ylamines as CMH can be used to assay formation of reactive
oxidant species resulting from differently generated oxidative
stress, detecting a 10-fold lower superoxide radical level than
other spin-traps, thereby providing superior sensitivity for
quantification of superoxide radical in vitro. Moreover, it was
found that the use of EPR detection of CMH to measure
the formation of reactive oxidant species in blood is a very
sensitive and reproducible method. The superior sensitivity
of CMH for superoxide detection provides a relevant method
to assay superoxide and other reactive oxidant species able
to induce oxidative stress under different experimental con-
ditions. Among all tested hydroxylamines, CMH showed
very high cellular accumulation and the highest rate of
intracellular nitroxide formation. In addition the high cell
permeability makes it suitable to detect both extra- and
intracellular ROS production.
Till now, due to technical difficulties in directly assessing
oxidant levels in vivo, investigators have generally had to
rely on indirect oxidative stress measurements techniques. In
particular, redox system evaluation, so that the assessments of
oxidative damage biomarkers is widely adopted as standard
indirect method for the determination of ROS production.
The purpose of this study was to evaluate the usefulness
of the EPR technique for the study of ROS in biology and
medicine by applying an innovative analytical approach [16].
Data resulting from the parallel determination of ROS
production reported in Figure 2 well demonstrate the crucial
role played by the choice of the sample examined on the
results obtained, suggesting that great care must be taken
in setting parameters and experimental procedure. Indeed,
as can be easily observed, different results were collected in
the same resting subject, from peripheral capillary blood,
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with respect to venous samples. At the same time red blood
cells rather than plasma sample analysis gave different values
too. Indeed also the other blood corpuscular components
contribute to ROS production [23, 24]. Nevertheless their
preparation is a complex and time-consuming procedure: in
particular sample manipulation might affect results giving
rise to artifacts. Moreover, in the examined experimental
conditions, they constitute only a minimal part of total blood
amount. For all these reasons an analysis of corpuscular
components was not carried out here nor was it considered
peculiar to this study. As expected significantly lower ROS
production rate levels were found from plasma samples due
to the absence of RBC, the main ROS producing elements
in blood. Capillary blood data were found greater than those
collected on venous blood, owing to the different oxygen con-
centration in the sample (PO
2
= 100mmHg versus 75mmHg
resp.) showing that EPR data are extremely sensitive to PO
2
so that measurement have to be taken with great accuracy. At
the same time, erythrocytes’ samples were characterized by
the greatest levels due to the increased number of red cells
present in the sample. Nevertheless as shows from Figure 3 a
linear relationship with good correlation factor was anyway
found between capillary blood versus the other examined
samples. The high correlation (𝑅2 = 0.92) with venous
blood (Figure 3(a)) is expected due to the constant difference
between the PO
2
levels at rest condition.The good correlation
(𝑅2 = 0.73) with erythrocytes (Figure 3(c)), as expected,
reveals the sensitivity of EPR technique to the number of spin
involved in the measurement, at the same time suggesting
that care must be taken in assuring that the results are not
influenced by the hematocrit value. As a matter of fact, the
vast majority of the relevant human studies have measured
the redox status using plasma or serum. This choice was
adopted after considering that plasma better reflects tissue
redox status together with the ease of plasma collecting
procedure. Indeed a good correlation (𝑅2 = 0.82) between
ROS production rates in capillary blood and in plasma
samples (Figure 3(b)) assessed in parallel determinations
was found. All these considerations well validate our choice
to make determinations of Step II anyway using capillary
blood aiming to reduce the invasiveness of the method
and hence increase its clinical potential in pathological
enhancement.
The herein adopted method allows reliable, rapid, and
noninvasive measurement of the instantaneous ROS concen-
tration levels directly in human peripheral blood. Due to its
simplicity coupled with the high sensitivity and specificity of
EPR technique, its use has successfully been validated both at
rest and after interventions able to alter the redox status of a
living system [16].
Main aim of the second phase of the study (step II)
was to test whether the method was suitable to detect
significant differences in heterogeneous categories of sub-
jects, demonstrating its sensibility even under different both
physiological (i.e., aging) and pathological (sarcopenia, MCI,
and sALS) experimental conditions. The measurements of
blood oxidative stress markers, a currently common practice
in biomedical research, as indirect index of ROS production
in pathophysiological conditions was examined too and
correlation with EPR data was attempted.
Many reviews have been published regarding the oxida-
tive stress theory of aging [1, 25–27]. Substantially higher
levels of lipid peroxidation products have been observed
in aged compared with young subjects [28]. In our study
the observed ROS overproduction (Figure 4(a)), related to
the aging process, caused oxidative damage as attested by
increases in lipid peroxidation (Figure 4(d)) suggesting that
the data follow a trend where redox imbalance leads to an
activation of redox-sensitive transcription factors together
with subsequent generation of numerous proinflamma-
tory mediators. A common phenomenon in aging-related
pathologies is the discovery of ROS as a potential unifying
mechanism contributing to many of such diseases [29, 30].
In this study we focused on three types of pathological
status in the genesis of which oxidative stress is hypothesized
to be implicated: sarcopenia, Mild Cognitive Impairment,
and Amyotrophic Lateral Sclerosis. The aberrant oxidative
damage observed is likely to contribute to an imbalance that
may presage the onset of age-related loss of skeletal muscle
mass [31], cognitive impairment and neurodegenerative pro-
cess respectively.
Oxidative damage is highly relevant in neuronal tissue
since this latter is a postmitotic high oxygen consuming
tissue characterized by poor concentration of antioxidants
but rich in polyunsaturated fatty acids, biomacromolecules
most susceptible to oxidation. In addition, the tissue is
enriched with iron, which accumulates in brain as a function
of age like a potentially potent catalyst for oxidative species
formation. Indeed there is evidence that oxidative stress-
mediated protein aggregation may be the primary cause
of the neuronal death in several forms of aging-related
neurodegenerative diseases [32].
Regardless of etiology, there is irrefutable evidence for
some components of oxidative stress in all of these neu-
rodegenerative diseases, even if the unresolved question is
whether oxidative stress is a consequence of degenerative
processes initiated by some other factor.
As for sarcopenia, combined effects of aging and life-
long inactivity, related to ROS overproduction generating
oxidative damage, also play a role in regulating intracellular
signal transduction pathways, directly or indirectly involved
in skeletal muscle atrophy and alterations of muscle contrac-
tility.
It is important to underline that in all the examined
pathological conditions here, even if different in both pheno-
typic manifestations and disease targets, our measurements
reported common higher ROS production levels and corre-
sponding higher oxidative damage biomarker concentrations
(Figures 5(a) and 5(b)). Anyway the positive correlation
between ROS production rate levels and the corresponding
plasma TBARS and PC concentrations confirms, in healthy
and diseased groups, our previous observations made in
a homogeneous experimental group (young athletes) [16].
Although almost all oxidative stress biomarkers have been
criticized for their reliability (including those used in the
present study), it is apparent that, at rest, all changes
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indicating increased oxidative stress are directly related to
ROS production (Figure 5).
5. Conclusion
In conclusion, EPR technique was demonstrated to offer
unique advantages in the determination of free radicals and
paramagnetic species in biological samples. The method
adopted here is direct, definitive, noninvasive, sensitive, and
quantitative so that it can be identified as indispensable tool
in the study of oxidants and oxidative stress in free radical
biology and medicine.
Our results suggest that an exaggerated production of
ROSwill lead to extensive oxidative damage and alterations in
intracellular signal transduction, which subsequently might
contribute to cellular and organ dysfunction and age-related
reductions in stress tolerance. Indeed, in all experimental
conditions examined, it is apparent that, at rest, all changes
indicating increased oxidative stress are directly related to an
increase in ROS production. Even if oxidative stress is likely
not always the primary pathological insult, ROS production
plays a contributory role in the disease process.Therefore the
ROS production rate determination might be a hotspot on
disease progression, an efficacy drug screening, and even a
therapeutic target.
In conclusion the primary goal of demonstrating the
adopted method here like an automated technique for a lot of
routine in clinical trials has been successfully achieved. Aware
that it’s hard to consider EPR a diagnostic tool as extensively
and widely utilized as clinical Nuclear Magnetic Resonance,
we think EPR may be able to provide useful information in a
way that offers significant advantages over other approaches.
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